ESR1 and neoplasm: Anti-estrogens target multiple cell types within the ER+ TME, including not only tumor cells and multiple immune cells of both the lymphoid and myeloid lineages, but also many other stromal components, such as heterogeneous fibroblasts, adipocytes and endothelial cells, in a dynamic extracellular matrix, which can further modify the immune environment [7].